Compare DRUG & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRUG | BVS |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.4M | 783.2M |
| IPO Year | 2020 | 2016 |
| Metric | DRUG | BVS |
|---|---|---|
| Price | $78.45 | $14.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $129.25 | $14.00 |
| AVG Volume (30 Days) | 176.6K | ★ 810.2K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 163.46 |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $568,087,000.00 |
| Revenue This Year | N/A | $7.52 |
| Revenue Next Year | N/A | $7.06 |
| P/E Ratio | ★ N/A | $27.56 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.00 | $6.26 |
| 52 Week High | $123.75 | $15.89 |
| Indicator | DRUG | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 61.47 |
| Support Level | $76.54 | $7.29 |
| Resistance Level | $83.65 | $15.89 |
| Average True Range (ATR) | 3.86 | 0.78 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 37.03 | 51.67 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.